Drug duo targets rare HER2 cancers in new trial
NCT ID NCT06136897
First seen Dec 16, 2025 · Last updated May 24, 2026 · Updated 24 times
Summary
This study tests a combination of two targeted drugs, trastuzumab and pertuzumab, in people with cancers that have a specific gene change called HER2 amplification. The cancers treated are not breast, stomach, or colorectal cancers. The goal is to see if the drug pair can shrink tumors or stop them from growing. About 35 adults with advanced solid tumors are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.